Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02049450
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
- Conditions
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02041429
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
- Conditions
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 149
- Registration Number
- NCT02038036
- Locations
- 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 13
- Registration Number
- NCT02015208
- Locations
- 🇨🇦
Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 125
- Registration Number
- NCT01981850
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 432
- Registration Number
- NCT01969838
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01965119
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wonju, Korea, Republic of
🇰🇷Dong-A University, Busan, Korea, Republic of
🇰🇷Busan University Hospital, Busan, Korea, Republic of
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 12
- Registration Number
- NCT01950780
- Locations
- 🇺🇸
Columbia University Medical Center, Department of Dermatology, New York, New York, United States
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 4
- Registration Number
- NCT01914484
- Locations
- 🇨🇦
Princess Margaret Hospital / University Health Network, Toronto, Ontario, Canada
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01895842
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.